Dr. Short is a cofounder of BioAtla© and co-inventor of the BioAtla's patented Conditionally Active Biologics (CAB) platform. He also cofounded Diversa Corporation (now BASF), a pioneering developer of enzymes, antibodies and biologically active compounds, and served in multiple roles including CEO, President and CTO from 1994 to 2005. He led Diversa's public offering, raising over $200 million, which was the largest biotechnology IPO at that time. Prior to Diversa, Dr. Short served as President of Stratacyte, an antibody engineering company and subsidiary of Stratagene (now Agilent), which together with Scripps Clinic was the first to clone and screen human antibody libraries in E. coli. During this time he also served as VP of R&D and Operations for Stratagene Cloning Systems. Dr. Short received his B.A in Chemistry with Honors from Taylor University. At Case Western Reserve University he received his Ph.D. in Biochemistry with additional studies in Macromolecular Science. He is the author of more than 100 publications and is the inventor of over 500 issued patents.
In 2006, Dr. Short was shortlisted by the editors of Nature Biotechnology as one of the people who made the most significant contribution to biotech in the past decade. He is the recipient of numerous other awards, including Ernst & Young's Entrepreneur of the Year Award, the American Chemical Society's Henry F. Whalen, Jr. Award for Business Development, Adaptive Business Leaders' Innovations in HealthCare Gold Award, two of Connect's first place Most Innovative Product Awards, and in 2010 received an international Best-of-the-Best award from the Young Presidents Organization (YPO). Dr. Short's board experience includes 15 years as a director of Invitrogen (now Thermo Fisher), Senomyx, and Taxon Biosciences (now Dupont). He is a member of YPO/WPO and a founder of Capia IP and the E.O. Wilson Biodiversity Foundation. Dr. Short serves as an advisor to educational, commercial, scientific and charitable organizations.
What is Jay M. Short's net worth?
The estimated net worth of Jay M. Short is at least $1.70 million as of December 20th, 2023. Dr. Short owns 1,439,283 shares of BioAtla stock worth more than $1,698,354 as of December 19th. This net worth estimate does not reflect any other assets that Dr. Short may own. Additionally, Dr. Short receives an annual salary of $1,130,000.00 as CEO at BioAtla. Learn More about Jay M. Short's net worth.
What is Jay M. Short's salary?
How do I contact Jay M. Short?
Has Jay M. Short been buying or selling shares of BioAtla?
Jay M. Short has not been actively trading shares of BioAtla over the course of the past ninety days. Most recently, on Wednesday, December 20th, Jay M. Phd Short bought 50,000 shares of BioAtla stock. The stock was acquired at an average cost of $2.14 per share, with a total value of $107,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,439,283 shares of the company's stock, valued at $3,080,065.62. Learn More on Jay M. Short's trading history.
Who are BioAtla's active insiders?
Are insiders buying or selling shares of BioAtla?
During the last year, BioAtla insiders bought shares 3 times. They purchased a total of 74,000 shares worth more than $157,320.00. The most recent insider tranaction occured on December, 26th when Director Sylvia Mcbrinn bought 4,000 shares worth more than $9,320.00. Insiders at BioAtla own 11.5% of the company.
Learn More about insider trades at BioAtla. Information on this page was last updated on 12/26/2023.
